DEFINITION

A chronic pruritic disorder characterized by multiple, firm, hyperkeratotic nodules resulting from a self-perpetuating itch–scratch cycle.

ETIOPATHOGENESIS

• Central mechanism: Chronic pruritus → repeated scratching → neural + epidermal remodeling → more itch

• Considered a disorder of neuroimmune dysregulation

Key drivers:

• ↑ cutaneous nerve fibers (hyperinnervation)

• ↑ pruritogenic cytokines (especially IL-31)

• Neural sensitization (peripheral + central)

Associations (high-yield):

• Atopic dermatitis

• Chronic renal failure

• Cholestatic liver disease

• HIV infection

• Psychiatric disorders (anxiety, OCD-like scratching)

• Neuropathic itch

CLINICAL FEATURES

• Multiple firm, dome-shaped or hyperkeratotic nodules

• Intensely pruritic (defining feature)

• Symmetrical distribution

• Common sites: extensor surfaces (arms, legs), trunk

• “Picker’s nodules”: excoriated, crusted lesions

• Surrounding skin often shows lichenification

HISTOPATHOLOGY

1. FOUNDATIONS

• Epidermis: Keratinocyte proliferation and barrier function

• Dermis: Contains collagen, vessels, immune cells, and nerve fibers

• Cutaneous nerves: Transmit itch sensation (C-fibers)

• Immune cells: Release cytokines influencing itch (e.g., IL-31)

2. INITIATING EVENT

• Initial trigger: chronic pruritus (systemic, dermatologic, or neuropathic origin)

• Earliest abnormality: persistent scratching-induced epidermal injury

3. PATHOGENESIS

1. Chronic itch → repeated scratching/rubbing

2. Mechanical trauma → epidermal hyperproliferation

3. Keratinocyte activation → cytokine release (IL-31, NGF)

4. Nerve growth factor (NGF) → neural hyperplasia

5. Increased nerve density → heightened itch perception

6. Cycle amplifies → itch–scratch vicious loop

4. HISTOPATHOLOGY

Epidermis:

• Marked hyperkeratosis

  • Excess keratin due to chronic mechanical stimulation

• Acanthosis

  • Thickened epidermis from keratinocyte proliferation

• Irregular elongation of rete ridges

  • Reflects chronic epidermal hyperplasia

• Hypergranulosis

  • Increased granular layer due to repeated friction

Dermis:

• Vertical collagen bundles (fibrosis)

  • Result of chronic scratching and repair

• Increased nerve fibers

  • Explains persistent pruritus

• Mixed inflammatory infiltrate (lymphocytes, histiocytes ± eosinophils)

Excoriation changes:

• Ulceration, crusting (secondary to scratching)

5. TEMPORAL EVOLUTION

• Early: Mild acanthosis + superficial inflammation

• Established: Hyperkeratosis + nodular architecture + neural hyperplasia

• Late: Fibrosis + lichenification + persistent nodules

6. NAMING LOGIC & TERMINOLOGY

• “Prurigo” → intensely itchy condition

• “Nodularis” → nodular lesions

• “Hyde prurigo” → eponym describing chronic nodular prurigo

• Acanthosis: epidermal thickening

• Hyperkeratosis: thickened stratum corneum

• Lichenification: skin thickening from chronic rubbing

7. STAINING & MARKERS

• H&E:

  • Highlights epidermal hyperplasia and dermal fibrosis

• Immunohistochemistry (if needed):

  • ↑ nerve fibers (PGP 9.5, S-100) → confirms neural proliferation

• No specific diagnostic stain (clinical correlation essential)

8. PATTERN RECOGNITION & DIAGNOSTIC LOGIC

Key pattern:

• Hyperkeratotic nodule + acanthosis + dermal fibrosis + neural hyperplasia

Diagnostic clues:

• Severe pruritus + nodules in accessible areas → think PN

Differentiate from:

• Lichen simplex chronicus → plaques, not nodules

• Hypertrophic lichen planus → violaceous, Wickham striae, basal damage

• Nodular scabies → burrows, genital involvement

• Dermatofibroma → firm but not pruritic

9. CLINICO-PATHOLOGICAL CORRELATION

• Hyperkeratosis + acanthosis → firm, thick nodules

• Neural hyperplasia → severe persistent itch

• Dermal fibrosis → nodular consistency

• Excoriations → crusting and bleeding clinically

MANAGEMENT

Core principle:

Break the itch–scratch cycle

First-line:

• Potent topical corticosteroids (↓ inflammation, ↓ itch)

• Intralesional steroids (flatten nodules)

Systemic:

• Antihistamines (limited effect but used)

• Gabapentin/pregabalin (neuropathic itch control)

• Antidepressants (e.g., SSRIs, mirtazapine)

Advanced therapy:

• Phototherapy (NB-UVB)

• Biologics:

  • Dupilumab (targets IL-4/IL-13 axis)

  • Nemolizumab (targets IL-31 pathway → high-yield emerging therapy)

Behavioral:

• Habit reversal therapy (important but often overlooked)

PROGNOSIS

• Chronic, relapsing

• Difficult to treat

• Improves only if itch cycle is interrupted

EXAM-FOCUSED INSIGHTS

• Itch precedes lesion (key concept)

• Nodules are secondary to scratching

• Neural hyperplasia explains refractory pruritus

• Strong link with systemic pruritic disorders

• Treatment failure common if behavioral aspect ignored

MUST-KNOW QUESTIONS

1. What is the primary mechanism in prurigo nodularis?
   Itch–scratch cycle

2. What precedes the nodules?
   Chronic pruritus

3. Key histological epidermal change?
   Acanthosis with hyperkeratosis

4. Why is itch severe in PN?
   Increased nerve fiber density

5. Most important cytokine in pruritus?
   IL-31

6. What is the role of NGF?
   Promotes nerve proliferation

7. Difference from lichen simplex chronicus?
   PN = nodules; LSC = plaques

8. Key dermal feature?
   Vertical collagen bundles (fibrosis)

9. First-line treatment?
   Potent topical corticosteroids

10. Emerging targeted therapy?
    Nemolizumab (anti–IL-31)

11. Why is treatment difficult?
    Persistent itch–scratch cycle

12. Common associated systemic condition?
    Chronic renal failure

13. What are the three key histological features that define prurigo nodularis?

    • A: (1) Marked, irregular acanthosis with hyperkeratosis, (2) vertically oriented collagen fibers in the dermis, and (3) dermal neural hyperplasia (confirmed by S100 staining).

14. What is the pathophysiological difference between lichen simplex chronicus (LSC) and prurigo nodularis (PN)?

    • A: Both are lichenification from rubbing/scratching. LSC is a localized, well-circumscribed plaque of thickened skin, with less dramatic histology. PN consists of discrete, palpable nodules with massive vertical collagen and a far more pronounced neurogenic component with significant discernible nerve hyperplasia on biopsy. They are on a spectrum.

15. A renal dialysis patient presents with severe generalized itch and excoriated nodules on the extensor limbs. Name the condition and the first-line anti-pruritic agent that targets the nervous system.

    • A: Uremic prurigo/prurigo nodularis. First line: Gabapentin or pregabalin.

16. Why must one consider a skin biopsy from a prurigo nodule for special stains like S100?

    • A: To demonstrate neural hyperplasia, which helps confirm the diagnosis over other hypertrophic dermatoses. More importantly, to rule out other causes of a nodular lesion, most critically cutaneous lymphoma (mycosis fungoides), which can present with therapy-resistant pruritic nodules.

17. What is the "butterfly sign" in prurigo nodularis?

    • A: Sparing of the mid-upper back, which corresponds to the area the patient cannot physically reach to scratch, forming the shape of a butterfly. This highlights the mechanically-driven nature of the lesion distribution.